{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:57:49Z","timestamp":1761058669575},"reference-count":17,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2007,4,28]],"date-time":"2007-04-28T00:00:00Z","timestamp":1177718400000},"content-version":"vor","delay-in-days":4622,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[1994,9]]},"abstract":"<jats:p>In a placebo\u2010controlled, randomized, and double\u2010blind 1\u2013day field study, the efficacy and onset of action of capsule acrivastine 8 mg were evaluated in 42 patients suffering from allergic rhinoconjunctivitis elicited by natural grass pollen exposure. Before and for 2 h after treatment, the patients scored the severity of five rhinoconjunctivitis symptoms every 10 min on a 0\u20135 scale (0 = no symptoms; 5 = very severe symptoms). The number of sneezes was recorded, and every 30 min, measurements of nasal peak flow were made. Before treatment, there was no difference in median total symptom score (mTSS) between the acrivastine group (A) and the placebo group (P) (12 and 12, respectively). Time of onset was estimated by an exponential decay model to be 19 min (95% confidence interval 0\u201339 min). A statistically significant difference in percent reduction of mTSS between A and P was observed for the first time 46 min after treatment start (A = 22%, P = 0%, <jats:italic>P<\/jats:italic> &lt;0.05). A 50% reduction in total symptom score (TSS) was achieved within 60 min by 38% in A and 17% in P (NS), and within 80 min in 52% and 17%, respectively (<jats:italic>P<\/jats:italic> &lt;0.05). The median time for 50% reduction in TSS (MT50) was 80 min for A and &gt; 120 min for P (<jats:italic>P<\/jats:italic> &lt;0.01). The symptom score of sneezing and number of sneezes were evaluated for periods of 30 min. The difference between A and P became statistically significant from 31\u201360 and 61\u201390 min, respectively (<jats:italic>P<\/jats:italic> &lt;0.05 and <jats:italic>P<\/jats:italic> &lt;0.01). Objective and subjective determinants in the different time intervals were well correlated. Improvement of nasal congestion was observed in A at 91\u2013120 min, as measured by nasal peak flow.<\/jats:p>","DOI":"10.1111\/j.1398-9995.1994.tb00131.x","type":"journal-article","created":{"date-parts":[[2007,5,14]],"date-time":"2007-05-14T00:09:04Z","timestamp":1179101344000},"page":"630-636","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of acrivastine in the treatment of allergic rhinitis during natural pollen exposure: onset of action"],"prefix":"10.1111","volume":"49","author":[{"given":"L.","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. R.","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bindslev\u2010Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. K.","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,4,28]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199141060-00008"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1977.tb01448.x"},{"key":"e_1_2_1_4_2","first-page":"47B","article-title":"French multi\u2010center double\u2010blind study to evaluate the efficacy and safety of acrivastine as compared with terfenadine in seasonal allergic rhinitis","volume":"17","author":"Gervais P","year":"1989","journal-title":"J Int Med Res"},{"issue":"4","key":"e_1_2_1_5_2","first-page":"100","article-title":"Histamine challenge and anterior nasal rhinometry: the nasal decongestant effect of BW 825C and tripolidine","volume":"30","author":"Gibbs TG","year":"1983","journal-title":"Folia Allergol Immunol Clin"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/00173138809428928"},{"key":"e_1_2_1_7_2","first-page":"345","article-title":"A new antihistamine (acrivastine) given for two weeks in seasonal allergic rhinitis (AR)","volume":"54","author":"Hampel FC","year":"1985","journal-title":"Ann Allergy"},{"key":"e_1_2_1_8_2","first-page":"1","article-title":"Astemizole, terfenadine, and loratadine: single\u2010dose study of onset of action in seasonal allergic rhinitis","volume":"9","author":"Knight A.","year":"1991","journal-title":"Today's Ther Trends"},{"issue":"2","key":"e_1_2_1_9_2","first-page":"3B","article-title":"Acrivastine \u2013 an evaluation of initial and peak activity in human skin","volume":"17","author":"Marks P","year":"1989","journal-title":"J Int Med Res"},{"key":"e_1_2_1_10_2","first-page":"436","article-title":"Double\u2010blind comparison of loratadine (SCH 29851), astemizole, and placebo in hay fever with special regard to onset of action","volume":"61","author":"Oei HD.","year":"1988","journal-title":"Ann Allergy"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1992.tb02387.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02270681"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1991.tb00545.x"},{"issue":"2","key":"e_1_2_1_14_2","first-page":"35B","article-title":"Comparison of the onset of H1\u2010antagonism with acrivastine and terfenadine by histamine bronchial challenge in volunteers","volume":"17","author":"Rolan PE","year":"1989","journal-title":"J Int Med Res"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315119"},{"key":"e_1_2_1_16_2","first-page":"19","article-title":"Onset of action of loratadine in seasonal allergic rhinitis","volume":"6","author":"Roman LS.","year":"1988","journal-title":"Today's Ther Trends"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(05)80210-6"},{"key":"e_1_2_1_18_2","unstructured":"Stokes TC Feinberg G.A study of the activity of the antihistamine acrivastine against histamine\u2010induced conjunctivitis. XIVth Congress of the European Academy of Allergology and Clinical Immunology Berlin (West) 17\u201322 September1989:125."}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1398-9995.1994.tb00131.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1398-9995.1994.tb00131.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T22:59:35Z","timestamp":1698188375000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1398-9995.1994.tb00131.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,9]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[1994,9]]}},"alternative-id":["10.1111\/j.1398-9995.1994.tb00131.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1398-9995.1994.tb00131.x","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,9]]}}}